GlaxoSmithKline (GSK)

AstraZeneca Warns Of Higher Costs As Drug Sales Slide

Bayer Divestment of its MaterialScience Unit ‘Inevitable,’ Analysts Say

Why China Pays Over The Odds For Its Medicines

Europe Backs New Dual-Action Novartis Lung Drug

Foreign Pharma Companies Could Be Probed In China

Bexsero Setback hits Novartis’ Vaccine Division

Andrew Witty: GSK’s China Corruption Scandal Will Hit Business

China Pharma Probe Widens, U.S. Citizen Detained

GSK Says Executives Appear To Have Broken Chinese law

GSK Boss To Address China Scandal At Results

China Widens Drug Industry Probe, Visits Belgium’s UCB

China Blocks GSK Finance Head From Leaving Country

China Launches Pharma Crackdown

Novartis Lifts Full-Year Outlook After Competition Delay

GlaxoSmithKline Broke Law to Boost Sales Prices, China Police say

China Says GSK Execs Confess To Bribery and Tax Crimes

GlaxoSmithKline to Use Immunocore Drug Technology

GlaxoSmithKline Examines Chinese Botox Sales Tactics

GlaxoSmithKline Hit with New Chinese Bribery Allegations

GlaxoSmithKline Under Investigation in China

Onyx Rejects Amgen Offer, Explores Possible Sale

Eisai Pulls Fycompa from German Market after Pricing Tiff

Sanofi’s Chris Viehbacher: EU’s Drug Data Stance Threatens Investment

Getting The Pulse

The Lion City - The Merlion - a mythical creature with the head of a lion and the body of a fish - is regarded as the Singapore icon ("Singapura" means "lion city" in Sanskrit). As one of the world's leading energy and chemical hubs, Singapore's contribution to the chemical industry is vast, both in terms of output and research.

Pfizer, GSK, and Siemens form R&D Consortium

Royalty Drops Hostile Bid For Ireland's Elan

FDA Panel Votes to Relax Avandia Restrictions

Ruling Threatens Royalty's Elan Bid Ahead of Key Meeting

GSK Bets on Chimp Virus with $321 Million Vaccines Buy

AstraZeneca Buys Heart Firm Omthera for up to $443 Million

Pfizer Takes its Shot at a Vaccine for Evasive Superbug

U.S. Government Taps GlaxoSmithKline for New Antibiotic

Elan Strikes $1 Billion Royalty Deal with Theravance

Drug Industry CEOs Plotting More Carve-outs

Big Drugmakers Think Small with Nanomedicine Deals